CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 448 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $6,211 | -20.8% | 115 | 0.0% | 0.00% | 0.0% |
| Q1 2024 | $7,838 | +8.9% | 115 | 0.0% | 0.00% | -33.3% |
| Q4 2023 | $7,199 | -74.1% | 115 | -81.2% | 0.00% | -72.7% |
| Q3 2023 | $27,779 | -39.3% | 612 | -24.9% | 0.01% | -35.3% |
| Q2 2023 | $45,754 | +24.1% | 815 | 0.0% | 0.02% | +6.2% |
| Q1 2023 | $36,862 | -10.7% | 815 | -19.7% | 0.02% | -30.4% |
| Q4 2022 | $41,260 | -69.4% | 1,015 | -50.8% | 0.02% | -73.6% |
| Q3 2022 | $135,000 | -6.2% | 2,065 | -12.7% | 0.09% | +3.6% |
| Q2 2022 | $144,000 | +94.6% | 2,365 | +103.0% | 0.08% | +68.0% |
| Q1 2022 | $74,000 | – | 1,165 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |